Gilead Wants Finnegan DQ'd In Hepatitis Drug IP Row
Gilead Sciences urged a Delaware federal judge on Friday to disqualify Finnegan Henderson Farabow Garrett & Dunner LLP from representing Idenix Pharmaceuticals Inc. in a suit alleging Gilead's recently approved hepatitis...To view the full article, register now.
Already a subscriber? Click here to view full article